LATEST

• BUSINESS Astellas’ Protein Degrader Setidegrasib Enters PIII in US
  April 1, 2026

• REGULATORY MHLW Updates Q&A on Use of Registry Data in Drug Applications
  April 1, 2026

• REGULATORY Japan Panel Designates Two Ebola Therapies for Early Approval Pathway
  April 1, 2026

• REGULATORY MHLW, METI Launch Joint Task Force to Safeguard Medical Supply Chains
  April 1, 2026

• BUSINESS Pfizer Hails Adult Rollout of Prevenar 20 as “Milestone” for Public Health
  April 1, 2026

• BUSINESS Kyorin Exercises Option for BIODOL’s Pain Drug Candidate
  April 1, 2026

• BUSINESS UCB Japan Files Zilbrysq Autoinjector in Japan
  April 1, 2026

• ACADEMIA Cancer Drug Supply Risks Spur Calls for Pricing Reform: JSMO
  March 31, 2026

• BUSINESS Tanabe Unveils PIII Data for EPP/XLP Therapy, Backing Filing Plans
  March 31, 2026

• BUSINESS Meiji Pharma Invests in Centivax to Support Vaccine R&D
  March 31, 2026

• BUSINESS Takeda’s Zasocitinib Logs Positive Results in Global PIII Psoriasis Trials
  March 31, 2026

• REGULATORY Japan Urges Priority Supply of Petroleum-Based Materials for Medical Devices
  March 31, 2026

• BUSINESS Ferring, Nippon Kayaku to Co-Promote Bladder Cancer Gene Therapy
  March 31, 2026

• BUSINESS Mochida to Acquire Urece from Fuji Yakuhin for 13.5 Billion Yen
  March 31, 2026

• BUSINESS Sumitomo Files Latuda for Pediatric Schizophrenia in Japan
  March 31, 2026

• BUSINESS Servier’s Glioma Drug Voranigo Now Available in Japan
  March 31, 2026

• ORGANIZATION JMA’s Ezawa Calls for “National Debate” on Drug Policy
  March 31, 2026

• ACADEMIA Japan Ophthalmology Society Flags Off-Label Concerns Ahead of Upneeq Launch
  March 30, 2026

• BUSINESS Otsuka to Acquire Transcend for US$700 Million, Snags PTSD Candidate
  March 30, 2026

• BUSINESS Eisai, MSD File Lenvima-Welireg Combo in Japan for RCC
  March 30, 2026

ページ

• « 先頭
• ‹ Prev
• …
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• Next ›
• 最終 »